Published: 2023-03-28 08:31:41 CEST
Company logo
J.Molner - Company Announcement
J.Molner submits second drug to Health Canada

J. Molner has successfully presented its second submission to Health Canada. Molner’s generic injectable antiemetic drug, MOC-002, is expected to be approved in Q2-Q3, 2024.

      For additional information please contact:
      
      Jason Grenfell-Gardner
      J.Molner AS
      Management Board member
      +372 536 00 346
      jason@jmolner.com
      
Market News Subscribe Nasdaq Baltic Nasdaq Europe
© 2025, Nasdaq, Inc. All Rights Reserved.